The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.

Described herein are compounds of Formula I:

##STR00001##

wherein R.sub.1-R.sub.6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

Described herein are compounds of Formula I:

##STR00001##

wherein R.sub.1-R.sub.6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

The present disclosure relates to compounds that act as protein kinase inhibitors, especially CK1δ and/or CK1ε inhibitors, which can be used to treat a serine threonine kinase-dependent disease and condition, such as neurodegenerative diseases like Alzheimer's Disease, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for neurodegenerative diseases, including Alzheimer's disease.

The present invention encompasses compounds and composition that inhibit Src kinase and methods of treating or preventing disorders associated therewith. In some embodiments, the invention encompasses compositions and combinations of agents that act synergistically inhibit the growth of cancer cells and particularly the compositions and combinations can be used for the treatment of cancer.

The present invention encompasses compounds and composition that inhibit Src kinase and methods of treating or preventing disorders associated therewith. In some embodiments, the invention encompasses compositions and combinations of agents that act synergistically inhibit the growth of cancer cells and particularly the compositions and combinations can be used for the treatment of cancer.

The present invention relates to methods of preparing ophthalmological compositions comprising latanoprost along with or replaced by other prostaglandin analogs (e.g., latanoprost derivatives or analogs), a stabilizing amount of a suitable and stabilizing polyoxyl castor oil (e.g., a hydrogenated polyoxyl castor oil), and one or more pharmaceutically acceptable excipients, wherein the composition remains stable when stored at room temperature conditions and/or accelerated conditions. Further, the invention also provides methods of use of the ophthalmological compositions for conditions including lowering intra-ocular pressure and treatment of glaucoma.

The present invention relates to methods of preparing ophthalmological compositions comprising latanoprost along with or replaced by other prostaglandin analogs (e.g., latanoprost derivatives or analogs), a stabilizing amount of a suitable and stabilizing polyoxyl castor oil (e.g., a hydrogenated polyoxyl castor oil), and one or more pharmaceutically acceptable excipients, wherein the composition remains stable when stored at room temperature conditions and/or accelerated conditions. Further, the invention also provides methods of use of the ophthalmological compositions for conditions including lowering intra-ocular pressure and treatment of glaucoma.